feed,title,long_url,short_url
Benzinga,Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis,https://www.benzinga.com/pressreleases/21/01/n19361210/harbour-biomeds-batoclimab-hbm9161-receives-china-cde-breakthrough-therapy-designation-for-treatme,https://j.mp/39rxMJD
